White & Case advises Bpifrance on its entry into Opella’s capital, alongside CD&R and Sanofi

Global law firm White & Case LLP has advised Bpifrance, the French public investment bank, on its strategic investment in Opella, representing 1.8 percent of the capital in the context of Sanofi's divestiture of its control.

The strategic investment is part of the finalization of the sale by Sanofi of a controlling 50 percent stake in Opella to CD&R, announced in October 2024. Sanofi retains a 48.2 percent stake in Opella, and Bpifrance's investment supports the creation of an independent global leader in consumer healthcare.

Opella, Sanofi's consumer healthcare business, is the third-largest over-the-counter business in the world, selling products such as Allegra, Doliprane and Dulcolax. The transaction is accompanied by the appointment of a Bpifrance representative to Opella's board of directors.

The White & Case team which advised on the transaction was led by partners Saam Golshani and Jean-Guillaume Meunier (both Paris) and included partners Estelle Philippi, Neeloferr Roy, Orion Berg (all Paris), James Turner (London), Thomas Glauden (Luxembourg & Brussels) and Guilhèm Becvort (Luxembourg), and associates Simon Martin-Gousset, Grégoire Berger, Sarah Kouchad, Martin Poirier (all Paris), Arvine Nooralian and Arnaud Marquet (both Luxembourg).

Press contact
For more information please speak to your local media contact.